Why carry out this study?

This study showed exenatide treatment resulted in HbA1c reduction similar to that of BIAsp30. However, HbA1c level does not reflect GV, and there has been accumulating evidence supporting the role of GV in the pathogenesis of T2DM-associated vascular complications, such as atherosclerosis and cardiovascular events

Using a CGMS, this study compared differences in GV in Chinese participants taking twice-daily exenatide or BIAsp30 whose T2DM was inadequately controlled with metformin monotherapy, which provided beneficial evidence for the use of exenatide in patients with T2DM

What was learned from the study?

Exenatide provided more improvement in postprandial glucose excursion, weight control, and attenuation of some oxidative stress and inflammatory markers without increased risk of hypoglycemia in Chinese patients with T2DM whose blood glucose was inadequately controlled with metformin

There was no difference in the change for the mean MAGE, LAGE, MODD, and SDBG between the Exenatide and BIAsp30 groups. Exenatide provided greater improvement in postprandial glucose excursion, weight control, and effective control of HbA1c without increasing hypoglycemic events. At the same time, the dosage of exenatide did not need to be titrated to blood glucose levels like the dosage of BIAsp30 requires. The results of this study provide new evidence to support the use of novel options for patients who choose insulin to further hypoglycemic treatment, especially in patients with obesity